Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carrie M Mosher

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Handbook of Experimental Pharmacology|March 6, 2010
Comparative and veterinary pharmacogenomicsCarrie M Mosher, Michael H Court
The Journal of Pharmacology and Experimental Therapeutics|March 5, 2009
CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistryCarrie M Mosher, Guoying Tai, Allan E Rettie
Biochemistry|October 17, 2008
Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9Carrie M Mosher, Matthew A Hummel, Timothy S Tracy, et al.
Journal of Medicinal Chemistry|April 27, 2013
Small-molecule inhibitors of cytokine-mediated STAT1 signal transduction in β-cells with improved aqueous solubilityStephen S Scully, Alicia J Tang, Morten Lundh, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 6, 2011
Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferasesStacie M Bratton, Carrie M Mosher, Farid Khallouki, et al.
Molecular Pharmacology|June 16, 2005
CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variantMatthew A Hummel, Charles W Locuson, Peter M Gannett, et al.
Science (New York, N.Y.)|September 16, 2017
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabineLeore T Geller, Michal Barzily-Rokni, Tal Danino, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Handbook of Experimental Pharmacology|March 6, 2010
Comparative and veterinary pharmacogenomicsCarrie M Mosher, Michael H Court
The Journal of Pharmacology and Experimental Therapeutics|March 5, 2009
CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistryCarrie M Mosher, Guoying Tai, Allan E Rettie
Biochemistry|October 17, 2008
Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9Carrie M Mosher, Matthew A Hummel, Timothy S Tracy, et al.
Journal of Medicinal Chemistry|April 27, 2013
Small-molecule inhibitors of cytokine-mediated STAT1 signal transduction in β-cells with improved aqueous solubilityStephen S Scully, Alicia J Tang, Morten Lundh, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 6, 2011
Analysis of R- and S-hydroxywarfarin glucuronidation catalyzed by human liver microsomes and recombinant UDP-glucuronosyltransferasesStacie M Bratton, Carrie M Mosher, Farid Khallouki, et al.
Molecular Pharmacology|June 16, 2005
CYP2C9 genotype-dependent effects on in vitro drug-drug interactions: switching of benzbromarone effect from inhibition to activation in the CYP2C9.3 variantMatthew A Hummel, Charles W Locuson, Peter M Gannett, et al.
Science (New York, N.Y.)|September 16, 2017
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabineLeore T Geller, Michal Barzily-Rokni, Tal Danino, et al.
Pageof 1